NCT03928314 - Study of ORIC-101 in Combination With Anticancer Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

September 22, 2022

Study Completion Date

December 4, 2023

Conditions

Solid Tumor

Interventions

DRUG

ORIC-101

ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle

DRUG

Nab-paclitaxel

75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle

Trial Locations (12)

Virginia Cancer Specialists, PC, Fairfax

Florida Cancer Specialists & Research Institute, Lake Mary

Florida Cancer Specialists & Research Institute, Sarasota

Tennessee Oncology NASH - SCRI - PPDS, Nashville

Mary Crowley Cancer Research Centers - Medical City, Dallas

University of Texas MD Anderson Cancer Center, Houston

NEXT Oncology, San Antonio

University of Colorado - PPDS, Aurora

University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Stanford Cancer Institute, Palo Alto

Oregon Health & Science University, Portland